How well can in vitro brain microcapillary endothelial cell models predict rodent in vivo blood-brain barrier permeability?

European Journal of Pharmaceutical Sciences

Volumn 43, Issue 3, 2011, Pages 109-124

  Avdeef, Alex ^a  

^a PION INC   (United States)

Author keywords

Blood brain barrier (BBB); Co culture; hCMEC D3; In situ brain perfusion; Paracellular permeability

Indexed keywords

ANIMAL CELL; ARTICLE; BIOPHYSICS; BLOOD BRAIN BARRIER; BRAIN MICROCAPILLARY ENDOTHELIAL CELL; BRAIN PERFUSION; CELL MEMBRANE PERMEABILITY; COW; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MICROCIRCULATION; NONHUMAN; POROSITY; PRIORITY JOURNAL; SWINE;

ALGORITHMS; ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CACO-2 CELLS; CAPILLARY PERMEABILITY; CATTLE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; MICE; MODELS, BIOLOGICAL; PERFUSION; PHARMACEUTICAL PREPARATIONS; RATS; REGRESSION ANALYSIS; SWINE; TIGHT JUNCTIONS;

EID: 79956337554     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2011.04.001     Document Type: Article

References (100)

1. Abbott, N.J., 2004. Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. Drug Discov. Today: Technol. 1, 407-416.
2. Abbott, N.J., 2007. In vitro models for examining and predicting brain uptake of drugs. In: Testa, B., van de Waterbeemd, H. (Eds.), Comprehensive Medicinal Chemistry II, Vol. 5. ADME-Tox Approaches, Elsevier, Amsterdam, pp. 301-320.
3. Abbott, N.J., Patabendige, A.A., Dolman, D.E., Yusof, S.R., Begley, D.J., 2010. Structure and function of the blood-brain barrier. Neurobiol. Discov. 37, 13-25.
4. Abbruscato, T.J., Williams, S.A., Misicka, A., Lipkowski, V., Hruby, V., Davis, T.P., 1996. Blood-to-central nervous system entry and stability of biphalin, a unique double-enkephalin analog, and its halogenated derivatives. J. Pharmacol. Exp. Ther. 276, 1049-1057.
5. Abbruscato, T.J., Thomas, S.A., Hruby, V.J., Davis, T.P., 1997. Blood-brain barrier permeability and bioavailability of a highly potent and μ-selective opioid receptor antagonist, CTAP: comparison with morphine. J. Pharmacol. Exp. Ther. 280, 402-409.
6. Adson, A., Raub, T.J., Burton, P.S., Barsuhn, C.L., Hilgers, A.R., Audus, K.L., Ho, N.F.H., 1994. Quantitative approaches to delineate paracellular diffusion in cultured epithelial cell monolayers. J. Pharm. Sci. 83, 1529-1536.
7. Allen, D.D., Smith, Q.R., 2001. Characterization of the blood-brain barrier choline transporter using the in situ rat brain perfusion technique. J. Neurochem. 76, 1032-1041. (Pubitemid 32167376)
8. Alsenz, J., Haenel, E., 2003. Development of a 7-day, 96-well Caco-2 permeability assay with high-throughput direct UV compound analysis. Pharm. Res. 20, 1961-1969.
9. Aoyagi, M., Agranoff, B.W., Washburn, L.C., Smith, Q.R., 1988. Blood-brain barrier transport of 1-aminocyclohexanecarboxylic acid, a nonmetabolic amino acid for in vivo studies of brain transport. J. Neurochem. 50, 1220-1226.
10. Audus, K.L., Rose, J.M., Wang, W., Borchardt, R.T., 1998. Brain microvessel endothelial cell culture systems. In: Pardridge, W.L. (Ed.), Introduction to the Blood-Brain Barrier: Methodology and Pathology. Cambridge University Press, Cambridge, UK, pp. 86-93.
11. Aungst, B.J., Nguyen, N.H., Bulgarelli, J.P., Oates-Lenz, K., 2000. The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds. Pharm. Res. 17, 1175-1180.
12. Avdeef, A., 2003. Absorption and Drug Development. Wiley-Interscience, New York, pp. 207-208.
13. Avdeef, A., 2010. Leakiness and size exclusion of paracellular channels in cultured epithelial cell monolayers-interlaboratory comparison. Pharm. Res. 27, 480-489.
14. Avdeef, A., Sun, N., 2011. A new in situ brain perfusion flow correction method for lipophilic drugs based on the pH-dependent Crone-Renkin equation. Pharm. Res. 28, 517-530.
15. Avdeef, A., Tam, K.Y., 2010. How well can the Caco-2/MDCK models predict effective human jejunal permeability? J. Med. Chem. 53, 3566-3584.
16. flux method. Eur. J. Pharm. Sci. 24, 333-349.
17. Begley, D.J., 2004. ABC Transporters and the blood-brain barrier. Curr. Pharm. Design 10, 1295-1312.
18. Bickel, U., 2005. How to measure drug transport across the blood-brain barrier. NeuroRx 2, 15-26. (Pubitemid 40128023)
19. Bickel, U., Schumacher, O.P., Kang, Y.-S., Voigt, K., 1996. Poor permeability of morphine-3-glucuronide and morphine-6-glucuronide through the blood-brain barrier in the rat. J. Pharmacol. Exp. Ther. 278, 107-113.
20. Bourasset, F., Cisternino, S., Temsamani, J., Scherrmann, J.M., 2003. Evidence for an active transport of morphine-6-β-D-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier. J. Neurochem. 86, 1564-1567. (Pubitemid 37174273)
21. Bradbury, M.W.B., Patlak, C.S., Oldendorf, W.H., 1975. Analysis of brain uptake and loss of radiotracers after intracarotid injection. Am. J. Physiol. 229, 1110-1115.
22. Butt, A.M., Jones, H.C., Abbott, N.J., 1990. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J. Physiol. 429, 47-62. (Pubitemid 20327537)
23. Cameron, I.R., Davson, H., Segal, M., 1969-1970. The effect of hypercapria on the blood-brain barrier to sucrose in the rabbit. J. Biol. Med. 42, 241-247.
24. Cecchelli, R., Berezowski, V., Lundquist, S., Culot, M., Renftel, M., Dehouck, M.-P., Fenart, L., 2007. Modelling of the blood-brain barrier in drug discovery and development. Nature Rev./Drug Discov. 6, 650-661. (Pubitemid 47202487)
25. Chen, W., Yang, J.Z., Anderson, R., Nielsen, L.H., Borchardt, R.T., 2002. Evaluation of the permeability characteristics of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs across the blood-brain barrier using an in situ perfused rat brain model. J. Pharmacol. Exp. Ther. 303, 849-857.
26. Chikhale, E.G., Ng, K.-Y., Burton, P.S., Borchardt, R.T., 1994. Hydrogen bonding potential as a determinant of the in vitro and in vivo blood-brain barrier permeability of peptides. Pharm. Res. 11, 412-419.
27. Chikhale, E.G., Burton, P.S., Borchardt, R.T., 1995. The effect of verapamil on the transport of peptides across the blood-brain barrier in rats: kinetic evidence for an apically polarized efflux mechanism. J. Pharmacol. Exp. Ther. 273, 298-303.
28. Cisternino, S., Rousselle, C., Dagenais, C., Scherrmann, J.-M., 2001. Screening of multidrug-resistence sensitive drugs by in situ brain perfusion in Pglycoprotein deficient mice. Pharm. Res. 18, 183-190.
29. Cisternino, S., Rousselle, C., Lorico, A., Rappa, G., Scherrmann, J.-M., 2003. Apparent lack of mrp1-mediated efflux at the luminal side of mouse blood-brain barrier endothelial cells. Pharm. Res. 20, 904-909.
30. Cisternino, S., Rousselle, C., Debray, M., Scherrmann, J.-M., 2003. In vivo saturation of the transport of vinblastine and colchicines by P-glycoprotein at the rat blood-brain barrier. Pharm. Res. 20, 1607-1611.
31. Cisternino, S., Rousselle, C., Debray, M., Scherrmann, J.-M., 2004. In situ transport of vinblastine and selected P-glycoprotein substances: implications for drug-drug interactions at the mouse blood-brain barrier. Pharm. Res. 21, 1382-1389.
32. Cisternino, S., Mercier, C., Bourasset, F., Rouse, F., Scherrmann, J.-M., 2004. Expression, up-regulation, and tranport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res. 64, 3296-3301. (Pubitemid 38581436)
33. Cornford, E.M., 1985. The BBB, a dopamine regulatory interface. Physiol. 7, 219-259.
34. Cussler, E.L., 1997. Diffusion-Mass Transfer in Fluid Systems, 2nd Ed. Cambridge Univ. Press, Cambridge, UK, pp. 111-121.
35. Dagenais, C. Blood-brain barrier transport of opioids and selected substrates: variable modulation of brain uptake by P-glycoprotein and countervectorial transport systems for the model opioid peptide [D-Pen2,5]-Enkephalin. Ph.D. Dissertation. Univ. of North Carolina, 2000.
36. Dagenais, C., Rousselle, C., Pollack, G.M., Scherrmann, J.-M., 2000. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J. Cereb. Blood Flow Metab. 20, 381-386.
37. Dagenais, C., Zong, J., Ducharme, J., Pollack, G.M., 2001. Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds. Pharm. Res. 18, 957-963.
38. Dagenais, C., Graff, C.L., Pollack, G.M., 2004. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem. Pharmacol. 67, 269-276.
39. Dagenais, C., Avdeef, A., Tsinman, O., Dudley, A., Beliveau, R., 2009. P-Glycoprotein deficient mouse in situ blood-brain barrier permeability and its prediction using an in combo PAMPA model. Eur. J. Pharm. Sci. 38, 121-137.
40. Fenstermacher, J.D., 1983. Drug transfer across the BBB. In: Breimer, D.D., Speiser (Eds.), Topics in Pharmaceutical Sciences. Amsterdam, Elsevier, pp. 143-154.
41. Fenstermacher, J.D., 1989. Pharmacology of the BBB. In: Neuwelt, E.A. (Ed.), Implications of the BBB and its maniputlation, Vol. 1. Plenum, NY, pp. 137-155.
42. Fernstermacher, J.D., Johnson, J.A., 1966. Filtration and reflection coefficients of the rabbit blood-brain barrier. Am. J. Physiol. 211, 341-346.
43. Förster, C., Silwedl, C., Golenhofen, N., Burek, M., Kietz, S., Mankertz, J., Drenckhahn, D., 2005. Occludin as direct target for glucocorticoid-induced improvement of blood-brain barrier properties in a murine in vitro system. J. Physiol. 565, 475-486. (Pubitemid 40879596)
44. Franke, H., Galla, H.-J., Beuckmann, C.T., 1999. An improved low-permeability in vitro-model of the blood-brain barrier: transport studies on retinoids, sucrose, haloperidol, caffeine and mannitol. Brain Res. 818, 65-71. (Pubitemid 29227284)
45. Franke, H., Galla, H.-J., Beuckmann, C.T., 2000. Primary cultures of brain microvessel endothelial cells: a valid and flexible model to study drug transport through the blood-brain barrier in vitro. Brain Res. Protoc. 5, 248-256.
46. Garberg, P., Ball, M., Borg, N., Cecchelli, R., Fenart, L., Hurst, R.D., Lindmark, T., Mabondzo, A., Nilsson, J.E., Raub, T.J., Stanimirovic, D., Terasaki, T., Oberg, J.-O., Osterberb, T., 2005. In vitro models for the blood-brain barrier. Toxicol. In Vitro 19, 299-334.
47. Gratton, J.A., Abraham, M.H., Bradbury, M.W., Schadka, H., 1997. Molecular factors influencing drug transfer across the blood-brain barrier. J. Pharm. Pharmacol. 49, 1211-1216.
48. Greig, N.H., Soncrant, T., Shetty, H.U., Momma, S., Smith, Q.R., Rapoport, S.I., 1990. Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. Cancer Chemother. Pharmacol. 26, 263-268.
49. Gumbleton, M., Audus, K.L., 2001. Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J. Pharm. Sci. 90, 1681-1698.
50. Hitchcock, S.A., 2008. Blood-brain barrier permeability considerations for CNS-targeted compound library design. Curr. Opin. Chem. Biol. 12, 1-6.
51. Ho, N.F.H., Raub, T.J., Burton, P.S., Barsuhn, C.L., Adson, A., Audus, K.L., Borchardt, R., 2000. Quantitative approaches to delineate passive transport mechanisms in cell culture monolayers. In: Amidon, G.L., Lee, P.I., Topp, E.M. (Eds.), Transport Processes in Pharmaceutical Systems. Marcel Dekker, New York, NY, pp. 219-316.
52. Hüwyler, J., Fricker, G., Torok, M., Schneider, M., Drewe, J., 1997. Transport of clonidine across cultured brain microvessel endothelial cells. J. Pharmcol. Exp. Ther. 282, 81-85.
53. Irvine, J.D., Takahashi, L., Lockhart, K., Cheong, J., Tolan, J.W., Selick, H.E., Grove, J.R., 1999. MDCK (Madin-Darby Canine Kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 88, 28-33.
54. Johnson, M.D., Anderson, B.D., 1999. In vitro models of the blood-brain barrier to polar permeants: comparison of transmonolayer flux measurements and cell uptake kinetics using cultured cerebral capillary endothelial cells. J. Pharm. Sci. 88, 620-625.
55. Karlsson, J., Artursson, P., 1991. A method for the determination of cellular permeability coefficients and aqueous boundary layer thickness in monolayers of intestinal epithelial (Caco-2) cells grown in permeable filter chambers. Int. J. Pharm. 71, 55-64.
56. Korjamo, T., Heikkinen, A.T., Waltari, P., Mönkkönen, J., 2008. The asymmetry of the unstirred water layer in permeability experiments. Pharm. Res. 25, 1714-1722.
57. Lee, K.-J., Johnson, N., Castelo, J., Sinko, P.J., Grass, G., Holme, K., Lee, Y.-H., 2005. Effect of experimental pH on the in vitro permeability in intact rabbit intestines and Caco-2 monolayer. Eur. J. Pharm. Sci. 25, 193-200.
58. Levin, V.A., 1980. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 23, 682-684.
59. Levin, V.A., Landahl, H.D., Freeman-Dove, M.A., 1976. The application of brain capillary permeability coefficient measurements to pathological conditions and the selection of agents which cross the blood-brain barrier. J. Pharmacokinet. Biopharm. 4, 499-519.
60. Liang, E., Chessic, K., Yazdanian, M., 2000. Evaluation of an accelerated Caco-2 cell permeability model. J. Pharm. Sci. 89, 336-345.
61. Liu, X., Tu, M., Kelley, R.S., Chen, C., Smith, B.J., 2004. Development of a computational approach to predict blood-brain barrier permeability. Drug Metab. Disp. 32, 132-139.
62. Lohmann, C., Huwel, S., Galla, H.-J., 2002. Predicting blood-brain barrier permeability of drugs: evaluation of different in vitro assays. J. Drug Target. 10, 263-276. (Pubitemid 34746308)
63. Lundquist, S., Renftel, M., Brillault, J., Fenart, L., Cecchelli, R., Dehouck, M.-P., 2002. Prediction of drug transport through the blood-brain barrier in vivo: a comparison between two in vitro cell models. Pharm. Res. 19, 976-981.
64. Mahar Doan, K.M., Humphreys, J.E., Webster, L.O., Wring, S.A., Shampine, L.J., Serabjit-Singh, C.J., Adkinson, K.K., Polli, J.W., 2002. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 303, 1029-1037.
65. Megard, I., Garrigues, A., Orlowski, S., Jorajuria, S., Clayette, P., Ezan, E., Mabondzo, A., 2002. A co-culture-based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation. Brain Res. 927, 153-167. (Pubitemid 34124122)
66. Momma, S., Aoyagi, M., Rapoport, S.I., Smith, Q.R., 1987. Phenylalanine transport across the blood-brain barrier as studied with the in situ brain perfusion technique. J. Neurochem. 48, 1291-1300. (Pubitemid 18001356)
67. Murakami, H., Takanaga, H., Matsuo, H., Ohtani, H., Sawada, Y., 2000. Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. Am. J. Physiol. Heart Circ. Physiol. 279, H1022-H1029.
68. Neuhoff, S., Ungell, A.-L., Zamora, I., Artursson, P., 2003. PH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm. Res. 20, 1141-1148.
69. Neuwelt, E., Abbott, N.J., Abrey, L., Banks, W.A., Blakely, B., Davis, T., Engelhardt, B., Grammas, P., Dedergaard, M., Nutt, J., Pardridge, W., Rosenberg, G.A., Smith, Q., Drewes, L.R., 2008. Strategies to advance translational research into brain barriers. Lancet Neurol. 7, 84-96. (Pubitemid 350258701)
70. Obradovic, T., Dobson, G.G., Shingaki, T., Kungu, T., Hidalgo, I.J., 2007. Assessment of the first and second generation antihistamines brain penetration and the role of P-glycoprotein. Pharm. Res. 24, 318-327.
71. Ohno, K., Pettigrew, K.D., Rapoport, S.I., 1978. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am. J. Physiol. 235, H299-H307.
72. Omidi, Y., Campbell, L., Barar, J., Connell, D., Akhtar, S., Gumbleton, M., 2003. Evaluation of the immortalized mouse brain capillary endothelial cell line, b.End3, as an in vitro blood-brain barrier model for drug uptake and transport studies. Brain Res. 990, 95-112. (Pubitemid 37247600)
73. Pardridge, W.M., 2004. Holy grails and in vitro blood-brain models. Drug Discov. Today 9, 258. (Pubitemid 38328509)
74. Pardridge, W.M., Mietus, L.J., 1979. Transport of steroid hormones through the rat blood-brain barrier. J. Clin. Invest. 64, 145-154.
75. Pardridge, W.M., Triguero, D., Yang, J., Cancilla, P.A., 1990. Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. J. Pharmacol. Exp. Ther. 253, 884-891.
76. Poller, B., Gutmann, H., Kraehenbuhl, S., Weksler, B., Romero, I., Couraud, P.-O., Tuffin, G., Drewe, J., Huwyler, J., 2008. The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J. Neurochem. 107, 1358-1368.
77. Rapoport, S.I., Ohno, K., Pettigrew, K.D., 1979. Drug entry into brain. Brain. Res. 172, 354-359.
78. Reed, D.J., Woodbury, D.M., 1962. Effect of hypertonic urea on cerebrospinal fluid pressure and brain volume. J. Physiol. London 164, 252-264.
79. Reichel, A., Begley, D.J., Abbott, N.J., 2003. An overview of in vitro techniques for blood-brain barrier studies. Methods Mol. Med. 89, 307-324.
80. Rice, A., Liu, Y., Michaelis, M.L., Himes, R.H., Georg, G.I., Audus, K.L., 2005. Chemical modification of paclitaxel (taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vivo. J. Med. Chem. 48, 832-838.
81. Simionescu, N., Simionescu, M., Palade, G.E., 1975. Permeability of muscle capillaries to small heme-peptides. Evidence for the existence of patent transendothelial channels. J. Cell Biol. 64, 586-607.
82. Skinner, R.A., Gibson, R.M., Rothwell, N.J., Pinteaux, E., Penny, J.I., 2009. Transport of interleukin-1 across cerebromicrovascular endothelial cells. Br. J. Pharmacol. 156, 1115-1123.
83. Smith, Q.R., 2000. Transport of glutamate and other amino acids at the blood-brain barrier. J. Nutr. 130, 10165-10225.
84. Smith, M., Omidi, Y., Gumbleton, M., 2007. Primary porcine brain microvascular endothelial cells: biochemical and functional characterization as a model for drug transport and targeting. J. Drug Target. 15, 253-268. (Pubitemid 47161493)
85. Summerfield, S.G., Read, K., Begley, D.J., Obradovic, T., Hidalgo, I.J., Coggon, S., Lewis, A.V., Porter, R.A., Jeffrey, P., 2007. Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J. Pharmacol. Exp. Ther. 322, 205-213.
86. Takasato, Y., Rapoport, S.I., Smith, Q.R., 1984. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol. 247, H484-H493.
87. Tanaka, H., Mizojiri, K., 1999. Drug-protein binding and blood-brain barrier permeability. J. Pharmacol. Exp. Ther. 288, 912-918.
88. Tavelin, S., Taipalensuu, J., Söderber, L., Morrison, R., Chong, S., Artursson, P., 2003. Prediction of oral absorption of low-permeability drugs using small intestine-like 2/4/A1 cell monolayers. Pharm. Res. 20, 397-405.
89. Terasaki, T., Ohtsuki, S., Hori, S., Takanaga, H., Nakashima, E., Hosoya, K.-I., 2003. New approaches to in vitro models of blood-brain barrier drug transport. Drug Discov. Today 8, 944-954. (Pubitemid 37230014)
90. Thiel-Demby, V.E., Humphreys, J.E., St.John Williams, L.A., Ellens, H.M., Shah, N., Ayrton, A.D., Polli, J.W., 2009. Biopharmaceutics Classification System: validation and learnings of an in vitro permeability assay. Mol. Pharm. 6, 11-18.
91. Thompson, A.M., 1970. Hyperosmotic effects on brain uptake of nonelectrolytes. In: Crone, C., Lassen, N.A. (Eds.), Capillary Permeability. Copenhagen, Munksgaard, pp. 459-467.
92. von Richter, O., Glavinas, H., Krajcsi, P., Liehner, S., Siewert, B., Zech, K., 2009. A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn-Schmiedeberg's Arch Pharmacol 379, 11-26.
93. Wang, Q., Rager, J.D., Weinstein, K., Kardos, P.S., Dobson, G.L., Li, J., Hidalgo, I.J., 2005. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int. J. Pharm. 288, 349-359.
94. Weksler, B.B., Subileau, E.A., Perrière, N., Charneau, P., Holloway, K., Leveque, M., Tricóire-Leignel, H., Nicotra, A., Bourdoulous, S., Turowski, P., Male, D.K., Roux, F., Greenwood, J., Romero, I.A., Couraud, P.O., 2005. Blood-brain barrier-specific properties of a human adult endothelial cell line. FASEB J. 19, 1872-1874. (Pubitemid 41598779)
95. Wu, D., Clement, J.G., Pardridge, W.M., 1998. Low blood-brain barrier permeability to azidothumidine (AZT), 3TC, and thymidine in the rat. Brain Res. 791, 313-316. (Pubitemid 28238342)
96. Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H., 2000. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur. J. Pharm. Sci. 10, 195-204.
97. Youdim, K.A., Qaiser, M.Z., Begley, D.J., Rice-Evans, C.A., Abbott, N.J., 2004. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic. Biol. Med. 36, 592-604.
98. Zhang, Y., Li, C.S.W., Ye, Y., Johnson, K., Poe, J., Johnson, S., Bobrowski, W., Garrido, R., Madhu, C., 2006. Porcine brain microvessel endothelial cells as an in vitro model to predict in vivo blood-brain barrier permeability. Drug Metab. Dispos. 34, 1935-1943.
99. Zhao, R., Kalvass, J.C., Pollack, G.M., 2009. Assessment of blood-brain barrier permeability using the in situ mouse brain perfusion technique. Pharm. Res. 26, 1657-1664.
100. Zhao, R., Raub, T.J., Sawada, G.A., Kasper, S.C., Bacon, J.A., Bridges, A.S., Pollack, G.M., 2009. Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substate efflux at the blood-brain barrier. Drug Metab. Dispos. 37, 1251-1258.